#VisualAbstract: BRAF and MEK inhibitor combination therapy shows efficacy for advanced melanoma in Japanese patients
Click to read the study in the European Journal of Cancer.
Tag: advanced melanoma
#VisualAbstract: Nivolumab plus ipilimumab is safe and effective for the treatment of advanced melanoma (CheckMate 218)
Click to read the study in Melanoma Research.
#VisualAbstract: Circulating tumor DNA levels may predict treatment response in patients with advanced melanoma
Click to read the study in The Lancet Oncology.
#VisualAbstract: BRAF/MEK inhibitor therapy may be associated with risk of uveitis in patients with advanced melanoma
Click to read the study in the European Journal of Cancer.
#VisualAbstract: Prognosis for advanced melanoma has improved between 2013 to 2017 for patients in the Netherlands
Click to read the study in the European Journal of Cancer.
#VisualAbstract: Long-term pembrolizumab monotherapy maintains efficacy despite the occurrence of immune-related adverse events in patients with advanced melanoma
Click to read the study in European Journal of Cancer
#VisualAbstract: Durvalumab, trametinib, and dabrafenib triplet therapy may provide robust immunogenicity in patients with BRAF-mutated advanced melanoma
Click to read the study in Nature Communications
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.